Companies › Epizyme
1 active drug program in 12 registered trials: 7 Phase 1, 4 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tazemetostat Histone-lysine N-methyltransferase EZH2 inhibitor | EZH2 | Phase 3 | Relapsed/Refractory Follicular Lymphoma; Peripheral Nerve Sheath Tumor; B-Cell Non-Hodgkin Lymphoma; Grade 3b Follicular Lymphoma … | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04917042 | Tazemetostat | Phase 2 | Peripheral Nerve Sheath Tumor | Oncology | Dec 2026 |
| NCT04846478 | Tazemetostat | Phase 1 | Metastatic Prostate Cancer | Oncology | Dec 2026 |
| NCT05407441 | Tazemetostat | Phase 1 | Atypical Teratoid Rhabdoid Tumor | Oncology | Feb 2027 |
| NCT04224493 | Tazemetostat | Phase 3 | Relapsed/Refractory Follicular Lymphoma | Oncology | Feb 2027 |
| NCT06242834 | Tazemetostat | Phase 2 | B-Cell Non-Hodgkin Lymphoma | Oncology | Apr 2027 |
| NCT05551936 | Tazemetostat | Phase 1 | Follicular Lymphoma | Oncology | May 2027 |
| NCT05627232 | Tazemetostat | Phase 1 | Recurrent Acute Myeloid Leukemia | Oncology | Jan 2028 |
| NCT02889523 | Tazemetostat | Phase 1 | Lymphoma | Oncology | Sep 2029 |
| NCT05890352 | Tazemetostat | Phase 2 | Grade 3b Follicular Lymphoma | Oncology | Dec 2029 |
| NCT05934838 | Tazemetostat | Phase 1 | Follicular Lymphoma | Oncology | Sep 2031 |
| NCT06824701 | Tazemetostat | Phase 1 | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Oncology | Jan 2032 |
| NCT05994235 | Tazemetostat | Phase 2 | Follicular Lymphoma | Oncology | Oct 2033 |
Novartis Evopoint Biosciences Daiichi Sankyo Hanmi Pharmaceutical Company
Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals FutureGen Biopharmaceutical (Beijing) CanariaBio pharmaand
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.